Reset filter
Nyckelord
Visa mer Nyckelord
Innehållsförteckning
  1. 1. Klinisk studie
  2. 2. Rutindokumentation
  3. 3. Register- och kohortstudier
  4. 4. Kvalitetssäkring
  5. 5. Datastandard
  6. 6. Frågeformulär för patienter
  7. 7. Medicinsk specialitet
    1. 7.1. Anestesi
    1. 7.2. Dermatologi
    1. 7.3. HNO
    1. 7.4. Geriatrik
    1. 7.5. Gynekologi och obstetrik
    1. 7.6. Invärtes medicin
      1. Hematologi
      1. Infektionssjukdomar
      1. Kardiologi och angiologi
      1. Pneumologi
      1. Gastroenterologi
      1. Nefrologi
      1. Endokrinologi och ämnesomsättning
      1. Reumatologi
    1. 7.7. Neurologi
    1. 7.8. Oftalmologi
    1. 7.9. Palliativ medicin
    1. 7.10. Patologi och rättsmedicin
    1. 7.11. Pediatrik
    1. 7.12. Psykiatri och psykosomatik
    1. 7.13. Radiologi
    1. 7.14. Kirurgi
      1. Allmänkirurgi och bukkirurgi
      1. Neurokirurgi
      1. Plastikkirurgi
      1. Hjärt- och thoraxkirurgi
      1. Akutkirurgi och ortopedi
      1. Kärlkirurgi
    1. 7.15. Urologi
    1. 7.16. Odontologi samt mun-, käk och ansiktskirurgi
Valda datamodeller

Du måste vara inloggad för att välja flera datamodeller, ladda ner dem eller analysera dem.

1344 Sökresultat.
Relevans Bedömning Nya först Gamla först

dbGaP phs000743 METSIM (METabolic Syndrome In Men) Study - pht005603.v2.p1

- 2022-12-13 - 8 Formulär, 1 Item-grupp, 31 Dataelement, 1 Språk
Item-grupp: pht005603
Principal Investigator: Markku Laakso, MD, PhD, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland MeSH: Metabolic Syndrome,Diabetes Mellitus, Type 2,Cardiovascular Diseases https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000743 The METSIM Study includes 10,197 men, aged from 45 to 73 years, randomly selected from the population register of the town of Kuopio, Eastern Finland, and examined in 2005-2010. The aim of the study is to investigate genetic and non-genetic factors associated with the risk of type 2 diabetes (T2D), cardiovascular disease (CVD), and insulin resistance-related traits in a cross-sectional and longitudinal setting. Study protocol includes collection of data on CVD risk factors (smoking, exercise, diet, history of chronic diseases including coronary heart disease, stroke, cardiac failure, medication, history of diabetes or early onset coronary heart disease in the family), questionnaire on the FINDRISC Score, measurement of height, weight, waist, hip, blood pressure, and bioimpedance for the evaluation of fat percentage. July 2016 - This first study release includes phenotype and whole exome sequencing data of n=982 participants in substudy: Type 2 Diabetes Genetic Exploration by Next-Generation Sequencing in Multi-Ethnic Samples (T2D-GENES) Project 1: Metabolic Syndrome in Men Study (METSIM) - phs001100.v2.p1. The second release (v2) includes phenotype data for the entire METSIM cohort and makes two additional substudies available, phs000919.v1.p1 and phs000752.v1.p1. *The METSIM Study v2 is utilized in the following dbGaP sub-studies.* To view genotypes, other molecular data, and derived variables collected in these sub-studies, please click on the following sub-studies below or in the "Sub-studies" section of this top-level study page phs000743.v2.p1 METSIM Study v2. - phs000752 METSIM FinMetSeq Exome Sequencing - phs000919 METSIM GWAS and Exome Chip - phs001100 METSIM T2D-GENES Exome Sequencing

pht005605.v1.p1

1 Item-grupp 5 Dataelement

pht010809.v1.p1

1 Item-grupp 6 Dataelement

pht004986.v1.p1

1 Item-grupp 3 Dataelement

pht004822.v2.p1

1 Item-grupp 4 Dataelement

pht004825.v1.p1

1 Item-grupp 3 Dataelement

Eligibility

1 Item-grupp 1 Dataelement

Eligibility Metabolic Syndrome NCT00655902

- 2018-06-15 - 1 Formulär, 2 Item-grupper, 16 Dataelement, 1 Språk
Item-grupper: Inclusion Criteria, Exclusion Criteria
Copenhagen Obesity Risk Assessment Study; ODM derived from: https://clinicaltrials.gov/show/NCT00655902

Eligibility Metabolic Syndrome NCT00170937

- 2016-10-19 - 1 Formulär, 2 Item-grupper, 10 Dataelement, 1 Språk
Item-grupper: Inclusion Criteria, Exclusion Criteria
A 16 Week Study to Evaluate the Effect on Insulin Sensitivity of Valsartan (320 mg) and Hydrochlorothiazide (25 mg) Combined and Alone, in Patients With Metabolic Syndrome; ODM derived from: https://clinicaltrials.gov/show/NCT00170937

dbGaP phs000737 NIDDK Genetics of Metabolic Syndrome in an Island Population - Eligibility

- 2022-12-28 - 6 Formulär, 1 Item-grupp, 1 Dataelement, 1 Språk
Item-grupp: IG.elig
Principal Investigator: Ranjan Deka, PhD, University of Cincinnati, Cincinnati, OH, USA MeSH: Metabolic Syndrome X,Diabetes mellitus type 2,Hypertension, Essential,Dyslipidemia,Coronary Heart Disease,Gout https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000737 The major objective of this study was to conduct a systematic genetic study of metabolic traits involved in metabolic syndrome through collection and analysis of epidemiological, demographic, environmental, and relevant biological and clinical data from a relatively isolated island population of the eastern Adriatic coast of Croatia. The population was chosen for the following reasons: 1) in spite of practicing a largely traditional life style and dietary habits, high rates of obesity, arterial hypertension, dyslipidemia and related metabolic abnormalities were found in previous studies; 2) the population was established by a relatively small number of founders, predominantly of Slavic descent from the mainland during 15th to 18th century AD, a genetically homogeneous population living in a homogeneous environment; 3) sharing a common European ancestry, a relevant population for study in the context of the general US population; 4) Croatian collaborators have been conducting anthropological and genetic studies in these communities for over three decades. There were two major aims of the study: 1) to recruit ~1200 adult participants and collect blood samples together with demographic, anthropometric, environmental and clinical data from the island of Hvar; to perform biochemical tests to measure glucose, insulin, uric acid and lipid levels; 2) conduct a genome-wide association analysis of metabolic traits and phenotypes using genome-wide SNP arrays (Affymetrix Genome-Wide Human SNP Array 5.0).

pht004443.v1.p1

1 Item-grupp 4 Dataelement

pht004444.v1.p1

1 Item-grupp 5 Dataelement

pht004445.v1.p1

1 Item-grupp 7 Dataelement

pht004446.v1.p1

1 Item-grupp 52 Dataelement

pht004447.v1.p1

1 Item-grupp 6 Dataelement

Eligibility Diabetes Mellitus NCT02310555

- 2021-09-27 - 1 Formulär, 2 Item-grupper, 14 Dataelement, 1 Språk
Item-grupper: Inclusion Criteria, Exclusion Criteria
Surgical Techniques in Diabetes Mellitus-II and Obesity. Metabolic Surgery Study (MSS); ODM derived from: https://clinicaltrials.gov/show/NCT02310555

Eligibility Type 2 Diabetes NCT00499148

- 2021-09-20 - 1 Formulär, 2 Item-grupper, 19 Dataelement, 1 Språk
Item-grupper: Inclusion Criteria, Exclusion Criteria
Efficacy Study Testing Herbal Extract on Metabolic Parameters in Subjects With Type 2 Diabetes; ODM derived from: https://clinicaltrials.gov/show/NCT00499148

Extension balance and metabolic disposition of vilanterol as a single oral dose. 106181 - Study Period

- 2018-12-11 - 1 Formulär, 17 Item-grupper, 85 Dataelement, 1 Språk
Item-grupper: Drug Screen, Ethanol Measurement, Physical Examination, Laboratory Procedures, Chemistry, Clinical, Laboratory Procedures, Hematology finding, Laboratory Procedures, Urinalysis, Pharmacokinetic aspects, Blood, Vital signs, 12-Lead-ECG, 12 lead ECG, Abnormality, Randomization, Numbers, Experimental drug, Therapeutic procedure, Confirmation, Pharmacokinetic aspects, Blood, Pharmacokinetic aspects, Blood, Metabolite, Pharmacokinetic aspects, Urine, Pharmacokinetic aspects, Faeces, Entero string test
Study ID: 106181 Clinical Study ID: B2C106181 Study Title: An open-label, single-arm study to determine the excretion balance and metabolic disposition of [14C]GW642444 administered as a single dose of an oral solution to healthy male volunteers Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01286831 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: vilanterol Trade Name: Study Indication: Pulmonary Disease, Chronic Obstructive

Extension balance and metabolic disposition of vilanterol as a single oral dose. 106181 - Study conclusion

- 2018-11-21 - 1 Formulär, 1 Item-grupp, 4 Dataelement, 1 Språk
Item-grupp: Study conclusion
Study ID: 106181 Clinical Study ID: B2C106181 Study Title: An open-label, single-arm study to determine the excretion balance and metabolic disposition of [14C]GW642444 administered as a single dose of an oral solution to healthy male volunteers Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01286831 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: vilanterol Trade Name: Study Indication: Pulmonary Disease, Chronic Obstructive

Eligibility Diabetes Type 2 NCT00940472

- 2019-11-19 - 1 Formulär, 2 Item-grupper, 18 Dataelement, 1 Språk
Item-grupper: Inclusion Criteria, Exclusion Criteria
Study on DMMET-01 Versus Metformin on Improvement of Metabolic Control in Naive Type 2 Diabetes Patients; ODM derived from: https://clinicaltrials.gov/show/NCT00940472

Extension balance and metabolic disposition of vilanterol as a single oral dose. 106181 - Follow-Up

- 2018-12-14 - 1 Formulär, 7 Item-grupper, 41 Dataelement, 1 Språk
Item-grupper: Physical Examination, Vital Signs, 12 lead ECG, 12 lead ECG, Abnormality, Laboratory Procedures, Chemistry, Clinical, Laboratory Procedures, Hematology finding, Laboratory Procedures, Urinalysis
Study ID: 106181 Clinical Study ID: B2C106181 Study Title: An open-label, single-arm study to determine the excretion balance and metabolic disposition of [14C]GW642444 administered as a single dose of an oral solution to healthy male volunteers Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01286831 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: vilanterol Trade Name: Study Indication: Pulmonary Disease, Chronic Obstructive

dbGaP phs000978 WGS of a malignant GCT with metabolic response to pazopanib - pht004941.v1.p1

- 2023-12-01 - 3 Formulär, 1 Item-grupp, 5 Dataelement, 1 Språk
Item-grupp: pht004941
Principal Investigator: Carl Morrison, MD, DVM, Roswell Park Cancer Institute, Buffalo, NY, USA MeSH: Granular Cell Tumor https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000978 We report one case study of a malignant granular cell tumor patient with metabolic response to pazopanib. In this study, we used whole-genome sequencing of the tumor with the matched blood to characterize the somatic mutation profile in this tumor. This is the first reported whole-genome sequencing study of the rare malignant granular cell tumor.

pht004942.v1.p1

1 Item-grupp 5 Dataelement

pht004943.v1.p1

1 Item-grupp 12 Dataelement

Eligibility Diabetes NCT00340938

- 2021-09-20 - 1 Formulär, 1 Item-grupp, 24 Dataelement, 1 Språk
Item-grupp: Criteria
Family Management of Childhood Diabetes Study; ODM derived from: https://clinicaltrials.gov/show/NCT00340938

Kontakt

Använd detta formulär för feedback, frågor och förslag på förbättringar.

Fält markerade med * är obligatoriska.

Hjälp

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial